Characterization of mucoadhesive nasal gels containing midazolam hydrochloride prepared from Linum usitatissimum L. mucilage by Basu, Shyamoshree & Bandyopadhyay, Amal Kumar
*Correspondence: S. Basu. NSHM College of Pharmaceutical 
Technology, 124, B. L. Saha Road, Kolkata, 700053, India. E-mail: 
shyamoshree.basu@nshm.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 47, n. 4, oct./dec., 2011
Characterization of mucoadhesive nasal gels containing midazolam 
hydrochloride prepared from Linum usitatissimum L. mucilage
Shyamoshree Basu1,*, Amal Kumar Bandyopadhyay2
*1NSHM College of Pharmaceutical Technology, West Bengal University of Technology, India,  
2Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
Nasal drug delivery systems prepared from natural materials are gaining importance in the field of 
pharmaceutical technology. Mucilage isolated from Linum usitatissimum L. (LUM) seeds was reported 
to be an effective natural mucoadhesive agent. The present study deals with a comparison of various 
characteristics of nasal gels containing midazolam hydrochloride (HCl) prepared from mucoadhesive 
agent extracted from Linum usitatissimum L. seeds and synthetic polymers like HPMC and Carbopol 
934P in terms of texture profile analysis, mucoadhesive strength, and in vivo drug absorption profiles. 
It was observed that gels formulated with the natural mucilage showed better results than the synthetic 
gels in all aspects like hardness, adhesiveness, cohesiveness and mucoadhesive strength. The absolute 
bioavailability of midazolam hydrochloride from the natural gel was 97.55% whereas that of synthetic 
gels was 57.33% and 76.81% respectively. 
Uniterms: Nasal drug/delivery systems. Midazolam hydrochloride/bioavailability. Linum usitatissimum L./
pharmacognosy. Linum usitatissimum L./mucoadhesive agent. Natural mucilage/nasal gel.  
Sistemas de liberação nasal preparados com produtos naturais estão ganhando importância no campo da 
tecnologia farmacêutica. A mucilagem isolada de sementes de Linum usitatissimum L. (LUM) mostrou-
se agente mucoadesivo eficaz. O presente estudo trata da comparação de várias características de géis 
nasais contendo cloridrato de midazolam preparados com agente mucoadesivo extraído das sementes 
de Linum usitatissimum L. e com polímeros sintéticos, como HPMC e Carbopol 943P, com relação ao 
perfil de textura, força mucoadesiva e perfis de absorção do fármaco in vivo. Observou-se que os géis 
formulados com mucilagem natural apresentam melhores resultados do que os sintéticos em todos os 
aspectos, como dureza, adesão, coesão e força mucoadesiva. A biodisponibilidade absoluta do cloridrato 
de midazolam a partir do gel natural foi de 97,55%, enquanto que nos géis sintéticos foi de 57,33% e 
76,81%, respectivamente. 
Unitermos: Gel nasal/sistema de liberação. Cloridrato de midazolam/biodisponibilidade. Linum 
usitatissimum L./farmacognosia. Linum usitatissimum L./agente mucoadesivo. Mucilagem natural/gel nasal. 
INTRODUCTION
Mucoadhesive nasal gels provide a firmer platform 
of drug delivery to the nasal cavity than other types of 
nasal formulations like solutions, sprays and insufflations, 
since the mucoadhesive agents make a better contact with 
the nasal mucosa, which helps enhancing drug bioavail-
ability. Various synthetic agents are available like HPMC, 
Carbopol 934P, sodium alginate and so on. Nowadays, 
natural mucilages are isolated from various plant parts and 
are used as mucoadhesive agents. It has been observed that 
natural materials are biocompatible and biodegradable, 
hence they are preferred to synthetic polymers. In our 
previous work, mucoadhesive nasal gels of midazolam 
were prepared from mucilages isolated from Linum usita-
tissimum L. seeds and it was observed that they gave better 
results than synthetic polymers in terms of viscosity and 
in vitro release profiles (Basu et al., 2009).
Linum usitatissimum L. mucilage is a water soluble 
heterogeneous polysaccharide composed of xylose, arabi-
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nose, glucose, galactose, galacturonic acid, rhamnose and 
fructose (Cui et al., 1994; Erskine et al., 1957; Hunt et 
al., 1962; Muralikrishna et al., 1987). It has good water-
holding capacities, owing to its marked swelling capacity 
and high viscosity in aqueous solution (Basu et al., 2009). 
It has been reported that the presence of many oligo- and 
polysaccharides in many substances imparts mucoadhe-
sive properties (Hunt et al., 1962). Since this mucilage is a 
rich source of polysaccharides and has remarkable swell-
ing capacity and high viscosity, it was selected to prepare 
nasal gels of midazolam.
Midazolam is a fast acting benzodiazepine with a 
short elimination half-life (1.8 to 6.4 hr) (Tschirch et al., 
2008). It is, therefore, a very useful drug for short minor 
procedures such as dental extraction. However, due to very 
poor bioavailability of this drug from the gastro-intestinal 
system (≈ 36%), it is administered through intramuscular 
injection only where bioavailability is over 90% (Lahat et 
al., 2000; Scheepers et al., 2000; Pecking et al., 2002; Har-
bord et al., 2004; Mahmoudian et al., 2004; McCormick et 
al., 2008). Nasal cavity is lined with a thin epithelial layer 
of mucosa and highly vascularized. Therefore, this route 
will be one of the best alternative routes of administration 
of this drug to intramuscular injection which is one of the 
most hazardous routes of drug administration as well as 
one of the most difficult to manufacture due to stringent 
its rules and regulations.
Hence, an attempt was made to prepare mucoad-
hesive nasal gels of midazolam, which may replace the 
conventional midazolam injection and widen the scope 
of novel drug delivery system.
The present study focuses on the preparation of 
mucoadhesive nasal gels containing midazolam hydro-
chloride (HCl) and on a comparison of texture profile 
analyses, mucoadhesive strengths and in vivo drug ab-
sorption profiles from nasal gels prepared with mucilage 
isolated from Linum usitatissimum L. seeds and synthetic 
polymers like HPMC and Carbopol 934P.
MATERIAL AND METHODS
Midazolam hydrochloride was obtained as a gift 
from Sun Pharmaceutical Industries Ltd., Gujarat, India. 
Linum usitatissimum L. seeds were purchased from the 
local market. HPMC, Carbopol 934P and sodium tau-
rocholate were purchased from Loba Chemie Pvt. Ltd., 
Mumbai, India. All other reagents and chemicals used 
were of analytical grade.
Preparation of nasal gel containing midazolam
Mucoadhesive nasal gels were prepared by dissolv-
ing midazolam hydrochloride in nasal solution that con-
sists of 0.65% NaCl, 0.04% KH2PO4, 0.09% K2HPO4 and 
0.02% benzalkonium chloride (pH 6), in a constant stir-
ring condition. Required amounts of LUM and synthetic 
polymers (HPMC and Carbopol 934P) and penetration 
enhancer like sodium taurocholate (0.5% w/v) were added 
to the solution and stirred on a magnetic stirrer until a 
uniform solution was obtained. This homogenous solution 
was kept at 4 °C overnight to allow complete swelling so 
that a homogenous gel was formed. The composition of 
nasal gels used in the present study is provided in Table I.
Characterisation of gels
Determination of texture profile analysis
Texture profile analyses of the gels were evaluated 
using QTS-25 Texture Analyser (Brookfield Engineering 
Labs., USA) to determine the mechanical parameters like 
hardness, cohesiveness and adhesiveness. An analytical 
probe of 1.2 cm in diameter was depressed twice into 
TABLE I - Composition of nasal gels along with formulation codes
Formulation
code
Midazolam HCl
 (%w/v) 
LUM
 (%w/v) 
HPMC
 (%w/v) 
Carbopol 934P
 (%w/v) 
Sodium taurocholate
 (%w/v)
F1 5.0 3.0 - - 0.5
F2 5.0  4.0 - - 0.5
F3 5.0 5.0 - - 0.5
F4 5.0 - 3.0 - 0.5
F5 5.0 - 4.0 - 0.5
F6 5.0 - 5.0 - 0.5
F7 5.0 - - 3.0 0.5
F8 5.0 - - 4.0 0.5
F9 5.0 - - 5.0 0.5
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each sample to a fixed depth (15 mm), at a defined rate 
(30 mm/min), with a defined recovery period (15 s), be-
tween the end of the first compression and the beginning 
of the second. A trigger force of 4 g was applied. At least 
six replicate analyses of each sample were performed at 
37±1°C. Data collection and evaluation were done by 
Texture pro software, version 2.1 (Cevher et al., 2008; 
Basu et al., 2010).
Evaluation of mucoadhesive strength
Mucoadhesive strengths of the gels were determined 
by measuring the force required to detach nasal mucous 
membrane from the gel using the same texture analyser. 
Freshly excised goat nasal membrane was attached to the 
upper probe of the instrument, and the fixed amount of gel 
was kept below that. The upper probe was then lowered 
at a speed of 10 mm/min to touch the surface of the gel. 
A force of 0.1 Newton was applied for 5 min to ensure 
intimate contact between the membrane and the gel. The 
surface area of exposed mucous membrane was 1.13 cm2.
Calibration curve of midazolam in rabbit plasma
Stock solutions of midazolam were prepared in a 
mixture of 10 mM phosphate buffer (pH 6.0): acetonitrile 
(80:20) to give final concentrations of 1 mg/mL. Plasma 
standards for calibration curves were prepared by spiking 
1.0 mL aliquots of pooled drug free plasma with 100 µL 
of the above mentioned working solutions, to make mid-
azolam plasma standards ranging from 10 to 1000 ng/mL.
In vivo drug absorption study
Selection of animals
The In vivo drug absorption study was conducted 
with prior approval of the Institutional Animal Ethics 
Committee and it was conducted according to the insti-
tutional guidelines of Animal Ethics Committee of Dr. B. 
C. Roy College of Pharmacy and Allied Health Sciences, 
West Bengal University of Technology, as recognized by 
the Committee for the Purpose of Control and Supervision 
on Experiments on Animals, India.
In vivo studies were conducted on 12 New Zealand 
albino male rabbits weighing between 2 and 2.5 kg. 
Based on results of texture profile analyses, mucoadhe-
sive strengths and in vitro drug release pattern (Basu et 
al., 2009), nasal gels containing 3% w/v LUM, 5% w/v 
Carbopol 934P and 5 % w/v HPMC along with 0.5% 
sodium taurocholate were selected for in vivo study. The 
animals were kept in individual metal cages and main-
tained at 25 °C for 10 days prior to the experiment. They 
were provided with standard diet and water ad libitum. 
The rabbits were kept in fasting condition for 24 h before 
the experiment commenced. The rabbits were grouped 
into four (group I, II, III and IV), each group contain-
ing three rabbits. Group I was administered intravenous 
bolus injection of midazolam. Groups II, III and IV were 
administered nasal gels of midazolam prepared with LUM, 
Carbopol 934P and HPMC. A single dose of midazolam 
(2 mg/kg body weight of rabbit) was administrated intra-
venously to compare the pharmacokinetic parameters. No 
anesthesia was used for the intravenous study. Midazolam 
was injected through cannulated marginal ear vein. After 
every 20 min, each rabbit was administered one-third of 
the initial dose of xylazine and ketamine intramuscularly 
to maintain a light plane of anesthesia. In case of nasal 
gels, the dose of midazolam administered was also 2 mg/
kg rabbit body weight.
Collection of blood samples
Two milliliters of blood samples were collected be-
fore intravenous injection and then at 5-, 10-, 15-, 20-, 30-, 
45-, 60-, 90-, 120-, 180-, 240- and 300-min intervals in ep-
pendorffs containing heparin sodium (100 U/mL). Imme-
diately after each blood sample collection, the catheter was 
flushed with 0.2 mL of a 10% (v/v) heparin/normal saline 
solution to prevent blood clotting inside the catheter. The 
blood samples were kept on ice and centrifuged at 3,000 
rpm for 10 min immediately after collection to separate 
the plasma and stored at −20 °C until the time of analysis.
HPLC analysis
Reverse phase HPLC was used to quantitate mid-
azolam in plasma samples. Midazolam was extracted with 
3 mL of cyclohexane/diethyl ether (3:7) after the addition 
of 10 μL of 2% sodium hydroxide (Shih et al., 2002). 
The organic phase was removed and evaporated to dry-
ness under nitrogen, and the residue was reconstituted in 
200 μL of the mobile phase (10 mM phosphate buffer (pH 
6.0)/acetonitrile, 80:20). From the mixture, 100 μL was 
injected for chromatographic analysis. The mobile phase 
consisted of phosphate buffer/acetonitrile (80:20) v/v. The 
mobile phase was delivered into the HPLC apparatus at a 
flow rate of 1 mL/min (isocratic pump, Model LC-10AS, 
Jasco, Japan). The detection wavelength was 218 nm (ul-
traviolet variable wavelength detector, Model SPD-10A), 
and a C18 column was used. All assays were performed at 
ambient temperature.
Pharmacokinetic analysis
Pharmacokinetic parameters like peak plasma con-
centration (Cmax), time to reach peak plasma concentration 
(tmax), area under the (concentration–time) curve (AUC), 
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mean residence time (MRT), elimination half-life (t1/2) 
and total body clearance (CL) were calculated following 
non-compartment model by Kinetica 4.4, PK/PD Analy-
sis, Thermoelectron Corporation. All the parameters were 
calculated for i.v. bolus injection of midazolam and in situ 
nasal gels. Fraction of dose absorbed (F) was calculated 
by the following equation:
where Dose(iv)=dose of midazolam given as i.v. solution, 
Dose(nasal)=dose of midazolam in nasal gels, AUC(i.v.)=AUC 
after i.v. administration of midazolam and AUC(nasal)=AUC 
after nasal administration of midazolam.
STATISTICS
Data were analyzed by one-way ANOVA followed 
by Tukey’s HSD test using Vassar stat software (USA). 
p<0.01 has been considered to be significant statistically.
RESULTS
The present study determines the various mechanical 
properties as well as mucoadhesive strengths of the gels 
with the help of QTS – 25 Texture Analyser. Results of the 
texture profile analysis and mucoadhesive strengths are 
tabulated in Table II. Hardness of LUM gels ranges from 
28.00 ± 1.11 g to 55.00 ± 0.38 g. In case of HPMC gels, it 
ranges from 11.00 ± 0.50 g to 18.00 ± 0.36 g and for Car-
bopol 934P it varies from 15.00 ± 0.51 g to 27.05 ± 0.32 g. 
Values of adhesiveness of LUM, HPMC and Carbopol 
934P gels varies from -89.00 ± 7.12 g to -112.08 ± 5.89 g, 
-30.60 ± 3.03 g to -51.26 ± 6.45 g and -45.03 ± 5.02 g to 
-80.36 ± 7.98 g, respectively. In a texture profile analysis 
graph, the curves of adhesiveness are obtained in the nega-
tive X-axis and hence, the values are negative. Cohesive-
ness of LUM gels ranges from 1.01 ± 0.05 to 0.97± 0.03. 
For HPMC gels, it varies from 1.15 ± 0.01 to 1.00 ± 0.03 
and for Carbopol 934P gels, it varies from 1.10 ± 0.05 to 
0.96 ± 0.03.
Values of mucoadhesive strengths of the gels are also 
displayed in Table II, which shows that with an increase 
in concentration of the gels from 3% to 5%, mucoadhe-
sive strengths of LUM gels varies from 16.26 ± 0.98 g to 
22.45 ± 1.02 g. For HPMC gels and Carbopol 934P gels, 
it ranges from 8.00 ± 0.85 g to 11.95 ± 0.56 g and from 
9.63 ± 1.02 g to 16.39 ± 0.89 g respectively. 
The calibration curve of midazolam hydrochloride 
prepared in rabbit plasma was found to be linear over 
the concentration range of 10-1,000 ng/mL (r2=0.9999). 
The experiment was repeated six times a day and for six 
consecutive days. Interday and intraday accuracy and 
precision values are displayed in Table III.
Plasma concentration–time profiles of midazolam 
TABLE II - Values of texture profile analysis and mucoadhesive strength of conventional gels. Data represent mean ± SD (n=6)
Formulation code Hardness (g) Adhesiveness (gs Cohesiveness Mucoadhesive strength (g)
F1 28.00 ± 1.11 -89.00 ± 7.12 1.01 ± 0.05 16.26 ± 0.98
F2 38.33 ± 0.69 -95.00 ± 2.65 0.99 ± 0.02 19.76 ± 0.85
F3 55.00 ± 0.38 -112.08 ± 5.89 0.97 ± 0.03 22.45 ± 1.02
F4 11.00 ± 0.50 -30.60 ± 3.03 1.15 ± 0.01 8.00 ± 0.85
F5 14.00 ± 0.48 -40.62 ± 4.88 1.02 ± 0.05 9.50 ± 0.36
F6 18.00 ± 0.36 -51.26 ± 6.45 1.00 ± 0.03 11.95 ± 0.56
F7 15.00 ± 0. 51 -45.03 ± 5.02 1.10 ± 0.05 9.63 ± 1.02
F8 21.00 ± 0.36 -69.36 ± 8.56 1.06 ± 0.04 13.22 ± 1.05
F9 27.05 ± 0.32 -80.36 ± 7.98 0.96 ± 0.03 16.39 ± 0.89
TABLE III - Interday and intraday accuracy and precision data for quantitation of midazolam in rabbit plasma
Amount of drug 
added (ng/mL)
Concentration in plasma (ng/mL) Accuracy Precision (% RSD)
Intraday Interday Intraday Interday Intraday Interday
10 9.91±0.24 9.55±0.38 99.10 95.50 2.42 3.97
200 199.05±2.15 195.99±4.51 99.53 98.46 1.08 2.30
600 599.30±2.65 596.08±3.58 99.88 99.34 0.44 1.10
1000 998.05±3.95 994.09±5.01 99.80 99.41 0.39 0.50
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TABLE IV - Comparative pharmacokinetic parameters of midazolam hydrochloride following administration of intravenous and 
nasal gels in rabbits (dose=2 mg/kg)
Pharmacokinetic 
parameters
Intravenous solution HPMC CP LUM
Cmax (ng/mL) 573.64 ± 5.23 151.47 ± 7.22 164.07 ± 6.85 181.12 ± 6.21
Tmax (min) - 60.00 ± 5.68 45.00 ± 3.66 30.00 ± 4.75
AUClast 32671.50 ± 90.56 18034.30 ± 101.45 22074.10 ± 96.72 26168.80 ± 123.67
AUCextra 865.87 ± 37.25 1191.83 ± 45.26 3684.71± 60.58 5546.92 ± 48.76
AUCtotal 33537.40 ± 101.25 19226.10 ± 97.25 25758.90 ± 95.46 31715.72 ± 98.77
MRT (min) 71.61 ± 5.05 130.16 ± 6.58 162.50 ± 7.25 190.07 ± 8.05
T1/2 (min) 58.78 ± 6.32 68.44 ± 5.28 99.68 ± 4.89 122.55 ± 5.87
Clearence X 10-5
(mg/ Kg*min/(ng/mL))
5.79 ± 6.95 10.11 ± 3.66 7.53 ± 2.89 6.67 ± 4.22
FIGURE 1 - Plasma concentration–time profiles of midazolam 
hydrochloride after administration of intravenous solution and 
the nasal gels in rabbits. Data represent mean ± SD (n=3).
122.55 ± 5.87, 68.44 ± 5.28 and 99.68 ± 4.89 min, re-
spectively.
DISCUSSION
The hardness of a gel determines the drug release 
pattern from the gel. From the results it can be said that 
gel containing 3% LUM showed optimum hardness. Ad-
hesiveness determines proper gel contact and retention 
at the site of application, thereby leading to enhanced 
bioavailability of the drug. In the present study, the ad-
hesiveness of gels was enhanced significantly with the 
increase in amount of mucoadhesive agent. Cohesiveness 
was observed to be reduced with the increase in amount 
of mucoadhesive agents. This happens because with an 
increase in amount of dispersed solids, that are the muco-
adhesive agents, the semisolid nature of the gels increased, 
which caused the gel to become less coherent (Cevher et 
al., 2008).
Mucoadhesive strength of LUM gels was found 
to be higher than those prepared with synthetic muco-
adhesive polymers and it increased with corresponding 
increase in concentration of mucoadhesive agent used. 
This may be due to the presence of certain functional 
groups in the mucilage, which were able to establish a 
more intimate contact with mucin of the mucosa (Basu 
et al., 2009).
In our previous work it was shown that sodium 
taurocholate produced better drug release profiles than 
sodium thioglycollate, and the histopathological study 
confirmed that LUM can be used safely as a mucoadhesive 
agent (Basu et al., 2009). Hence, for the in vivo study, na-
sal gels containing 0.5 % w/v sodium taurocholate were 
administered to the rabbits. Higher plasma concentration 
after administration of i.v. solution and the nasal gels are 
shown in Figure 1. Pharmacokinetic parameters were 
displayed in Table IV. Cmax values of i.v. injection, LUM, 
HPMC and Carbopol 934P gels were 573.64 ± 5.23, 
181.12 ± 6.21, 157.47 ± 7.22 and 164.07 ± 6.85 ng/mL, 
respectively. Tmax values of i.v. injection, LUM, HPMC 
and CP gels were 0.00, 30.00 ± 9.76, 60.00 ± 6.25 and 
45.00 ± 7.88 min, respectively. T1/2 values of i.v. injec-
tion, LUM, HPMC and CP gels were 58.78 ± 6.32, 
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of midazolam hydrochloride is observed in case of LUM 
gels in comparison to HPMC and Carbopol 934P gels 
(Figure 1), and accordingly, absolute bioavailabilities of 
midazolam from LUM, HPMC and Carbopol gels were 
reported to be 97.55%, 57.33% and 76.81%, respectively. 
From the in vivo study we can conclude that bioavailability 
of midazolam from nasal gels prepared from LUM was 
better than those prepared from synthetic polymers. This 
confirms that LUM can be effectively used as a mucoad-
hesive agent instead of synthetic polymers for delivery of 
midazolam via nasal route. 
CONCLUSION
From the above study, it is confirmed that mucoad-
hesive nasal gels of midazolam hydrochloride prepared 
with mucilage isolated from Linum usitatissimum L. 
seeds exhibited better mechanical properties as well as 
in vivo drug absorption pattern. Also, bioavailability of 
midazolam was higher from the gels prepared with this 
natural mucilage than from synthetic gels. Hence, this 
new dosage form of midazolam prepared with a natural 
mucilage is a safe and cost-effective form of nasal drug 
delivery system.
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